These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35494080)

  • 1. Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer.
    Li M; Zhang X; Bai X; Liang T
    Front Oncol; 2022; 12():862154. PubMed ID: 35494080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFR2: Role in Cancer Immunology and Immunotherapy.
    Yang Y; Islam MS; Hu Y; Chen X
    Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TNF/TNFR2 signaling pathway is a key regulatory factor in endothelial progenitor cell immunosuppressive effect.
    Naserian S; Abdelgawad ME; Afshar Bakshloo M; Ha G; Arouche N; Cohen JL; Salomon BL; Uzan G
    Cell Commun Signal; 2020 Jun; 18(1):94. PubMed ID: 32546175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNFR2: A Novel Target for Cancer Immunotherapy.
    Vanamee ÉS; Faustman DL
    Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.
    Sheng Y; Li F; Qin Z
    Front Immunol; 2018; 9():1170. PubMed ID: 29892300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFα/TNFR2 signaling pathway: an active immune checkpoint for mesenchymal stem cell immunoregulatory function.
    Beldi G; Khosravi M; Abdelgawad ME; Salomon BL; Uzan G; Haouas H; Naserian S
    Stem Cell Res Ther; 2020 Jul; 11(1):281. PubMed ID: 32669116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.
    Takahashi H; Yoshimatsu G; Faustman DL
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment.
    Mohd Salim NH; Mussa A; Ahmed N; Ahmad S; Yean Yean C; Hassan R; Uskoković V; Mohamud R; Che Jalil NA
    Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response.
    Moatti A; Cohen JL
    Front Cell Dev Biol; 2021; 9():725473. PubMed ID: 34712661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFα-TNFR2 signaling pathway in control of the neural stem/progenitor cell immunosuppressive effect: Different experimental approaches to assess this hypothetical mechanism behind their immunological function.
    Shamdani S; Uzan G; Naserian S
    Stem Cell Res Ther; 2020 Jul; 11(1):307. PubMed ID: 32698887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy.
    Medler J; Kucka K; Wajant H
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting TNFR2 for cancer immunotherapy: recent advances and future directions.
    Li L; Ye R; Li Y; Pan H; Han S; Lu Y
    J Transl Med; 2024 Sep; 22(1):812. PubMed ID: 39223671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNFR2-expressing CD4
    He J; Li R; Chen Y; Hu Y; Chen X
    Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4
    Islam MS; Yang Y; Chen X
    Adv Exp Med Biol; 2021; 1278():257-272. PubMed ID: 33523452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis.
    Ye LL; Peng WB; Niu YR; Xiang X; Wei XS; Wang ZH; Wang X; Zhang SY; Chen X; Zhou Q
    Ann Transl Med; 2020 Dec; 8(24):1647. PubMed ID: 33490159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
    Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
    Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.